Nevada Administrative Code
Chapter 639 - Pharmacists and Pharmacy
COMPOUNDING AND DISPENSING DRUG PRODUCTS
Standards for Compounding and Dispensing Sterile Products
Section 639.67061 - Low-risk sterile compounding: Process and storage
Universal Citation: NV Admin Code 639.67061
Current through September 16, 2024
1. A compounded drug product is a low-risk sterile compounded drug product if:
(a) The
compounded drug product is required to be sterile for its effective
administration;
(b) The sterile
compounded drug product is at a low risk of contamination; and
(c) One or more of the following conditions
are present:
(1) The compounding process
involves aseptic manipulations that are performed entirely within an
environment with an air quality of at least ISO Class 5 and uses only sterile
ingredients, products, components and devices;
(2) The compounding process involves only
transferring, measuring and mixing manipulations and uses not more than three
commercially manufactured sterile drug products or other entries of a sterile
drug product into one container, including, without limitation, a bag or vial,
to make the final compounded drug product;
(3) The manipulations needed to compound the
drug product are limited to aseptically opening ampules, penetrating sterile
stoppers on vials with sterile needles and syringes, and transferring sterile
liquids in sterile syringes to sterile administration devices, package
containers or other sterile drug products and containers for storage and
dispensing;
(4) The final
compounded drug product contains a volume of 15 milliliters or less of a
radiopharmaceutical and has an expiration time of 18 hours or less per dosage
unit, including, without limitation, a dosage unit of a radiopharmaceutical
prepared from an eluate by using a molybdenum-99technetiym-99m generator;
or
(5) The final compounded drug
product contains commercially manufactured cyclotron radiopharmaceuticals which
contain preservatives and which have expiration times of 72 hours or
less.
2. Unless sterility testing or potency limitations allow for a different period, the period of storage before administration of a low-risk sterile compounded drug product must not exceed:
(a) Forty-eight
hours at a controlled room temperature that is at least 20 degrees Celsius (68
degrees Fahrenheit) but not more than 25 degrees Celsius (77 degrees
Fahrenheit);
(b) Fourteen days at a
temperature that is at least 2 degrees Celsius (36 degrees Fahrenheit) but not
more than 8 degrees Celsius (46 degrees Fahrenheit); or
(c) Forty-five days in a solid frozen state
that is -10 degrees Celsius (14 degrees Fahrenheit) or colder.
Added to NAC by Bd. of Pharmacy by R035-06, eff. 9-18-2008
NRS 639.070
Disclaimer: These regulations may not be the most recent version. Nevada may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.